Perimenopause
- PMID: 39406411
 - PMCID: PMC11482657
 - DOI: 10.1503/cmaj.240337
 
Perimenopause
Conflict of interest statement
Competing interests:: Michelle Jacobson sits on advisory boards for Astellas, BioSyent, Duchesnay, Eisai, Knight, Lupin, Pfizer, Canadian Menopause Society, and Menopause Foundation of Canada. She has received honoraria, consulting fees, or both, from Astellas, AbbVie, Bayer, BioSyent, Duchesnay, Knight, Lupin, Organon, Pfizer, and Searchlight, grants or contracts from Health Canada and the Canadian Institutes of Health Research, and support to attend meetings from The Society of Obstetricians and Gynaecologists of Canada. No other competing interests were declared.
References
- 
    
- “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767–94. - PubMed
 
 - 
    
- Singh S, Best C, Dunn S, et al. . No. 292: Abnormal uterine bleeding in pre-menopausal women. J Obstet Gynaecol Can 2018;40:e391–415. - PubMed
 
 
MeSH terms
LinkOut - more resources
Full Text Sources